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Abstract 
Background: Sickle cell trait (SCT) or Hemoglobin S (HbS) trait which is due to inheritance of an abnormal hemo‑
globin (Hb) gene from one parent and a normal gene from the other has been known to be common among people 
of African descent. Individuals with SCT may find themselves in the blood donor population without knowing their 
‘carrier’ status and this may have severe consequences on their health as well as that of a recipient, particularly if they 
happen to be a sickle cell disease patient. The aim of the study was to determine the prevalence of HbS trait among 
blood donors.
Results: This cross‑sectional study employed convenience sampling method to recruit subjects. A total of 150 
prospective and healthy blood donors comprising 138 males and 12 females were involved in the study. Two (2) ml of 
venous blood was collected from each donor into K3EDTA tubes and analyzed using the sodium metabisulphite slide 
test and cellulose acetate Hb electrophoresis at alkaline pH (8.6) for Hb genotypes. Statistical Package for Social Sci‑
ences version 20.0 (SPSS 20.0) and Chi square were used to analyse the data obtained. Out of the 150 blood donors, 
133 (88.7 %) tested negative for sickling (131 were genotype AA and 2 were AC) and 17 (11.3 %) tested positive for 
sickling, all of whom were genotype AS.
Conclusion: The results of the study showed the existence of SCT among the blood donor population sampled. 
Taking blood from such people can harm their health as well as that of the recipient if they happen to be sickle cell 
disease (SCD) patients. It is therefore recommended that blood donors as well as donated blood units should be 
screened for SCT to avoid causing any harm to both the donor and recipient.
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Hypothesis
Sickle cell disease (SCD) refers to a group of disorders 
that affects hemoglobin (Hb), causing them to form 
abnormal hemoglobin S (HbS) molecules [1]. Affected 
people inherited the abnormal gene (HbS) from both par-
ents. A person who inherits an abnormal gene from one 
parent and a normal gene from the other has a sickle cell 
trait (SCT) or is said to be a carrier of SCD [2]. The gene 
for sickle cell disease is more common in Sub-Sahara 
Africa, Mediterranean countries, the Middle East and 
India [3]. The Hispanic population of both Spanish or 
Latin American descent is also at risk of the disease—at 
least 1 in 180 Hispanic births have sickle cell trait [4], [5].
Reports from studies conducted in Ghana show that 
about 25–30  % of the Ghanaian population carry the 
sickle cell trait and 2 % of newborns have sickle cell dis-
ease [6, 7]. Sickle cell disease is a major public health con-
cern, having socio-economic implications for the affected 
child as well as their family. Patients with SCD are often 
hospitalised for long periods [6, 8]. Also, death in early 
childhood as a result of SCD is high in Africa partly due 
to lack of comprehensive healthcare [9, 10].
Blood transfusion is an important act that saves mil-
lions of lives each year [11]. It is estimated that over 90 
million blood units are collected worldwide each year 
[12]. According to the WHO, four main types of blood 
Open Access
*Correspondence:  s.antwi‑baffour@chs.edu.gh 
Department of Medical Laboratory Sciences, School of Biomedical 
and Allied Health Sciences, College of Health Sciences, University 
of Ghana, P. O. Box KB 143, Korle‑Bu, Accra, Ghana
Page 2 of 6Antwi‑Baffour et al. BMC Res Notes  (2015) 8:583 
donors can be identified. They include: voluntary non-
remunerated donors; family/replacement/directed 
donors; paid/commercial donors and autologous donors 
[13]. In order to ensure a safe and sufficient blood sup-
ply, the WHO adopted a strategy that aimed to imple-
ment a national policy for each African country by 2012 
[14]. This included the recruitment of regular voluntary, 
healthy and non-remunerated blood donors. However, 
with the high prevalence (25–30 %) of sickle cell trait in 
Ghana, people who have the sickle cell trait may enrol 
as prospective blood donors since majority of them are 
asymptomatic and in stable condition [15, 16]. They 
may therefore find themselves in the donor population 
unknowingly. This may have severe consequences on 
their health after they have donated blood as well as that 
of the recipients particularly if they happen to have sickle 
cell disease.
Patients with SCD may require frequent blood trans-
fusion to treat complications associated with the disease 
[17, 18]. However, transfusing blood containing HbS to 
a SCD patient can increase the proportion of sickled red 
cells in the person’s circulation, inducing further sickling 
and causing occlusions in the microcirculation [19]. This 
deprives the tissues and organs of oxygen, resulting in 
vaso-occlusive crisis and affecting proper management of 
the patient [20]. In view of the above, this study sought 
to determine the prevalence of HbS trait among blood 




The study was a cross-sectional study carried out from 
May to July, 2014.
Study setting/participants
The study subjects were apparently healthy individuals 
between the ages of 17 and 60 years who came to donate 
blood at the southern area blood centre (SABC) of the 
Korle-bu Teaching Hospital, Accra. They included volun-
tary and replacement blood donors.
Ethical consideration
Ethical clearance for this research was sought from the 
Ethics and Protocol Review Committee at the School 
of Biomedical and Allied Health Sciences, University of 
Ghana, Legon. All the participants gave their informed 
consent before their samples were collected.
Materials
Some of the materials needed for the work include: EDTA 
tubes, 2  % Sodium metabisulphite, Physiological saline 
(0.85 %), Electrophoretic tank and power pack (Consort 
EV 243), Centrifuge, Cellulose acetate paper/membrane, 
Tris–EDTA Borate (TEB) buffer (pH 8.6), Carbon tetra-
chloride (CCl4), 5 % Acetic acid, Ponceau S stain.
Sample collection/analysis
One hundred and fifty (150) subjects, involving 138 
males and 12 females were recruited using convenience 
sampling method. Two millilitres (2  ml) of blood was 
collected from each of the participants during blood 
donation into labelled tri-potassium ethylene diamine 
tetra-acetic acid (K3EDTA) tubes and mixed gently. All 
samples were kept at 4–8 °C after which they were trans-
ported to the laboratory for analysis. Samples were pro-
cessed within 24 h after collection.
Sickling test (Sodium metabisulphite method)
Equal volumes of well-mixed EDTA anticoagulated blood 
and 2 % sodium metabisulphite were mixed on a cleaned 
labelled slide, covered with a cover slip and incubated at 
room temperature for at least 30 min. It was then exam-
ined microscopically, using the 40× objective for sickle 
cells. Sickle cells appeared crescent-shaped [21]. Positive 
and negative controls, from a known sickle cell trait per-
son and a person without the sickle cell trait respectively, 
were set-up alongside the test.
Hemoglobin electrophoresis (cellulose acetate method 
at alkaline pH)
The blood samples were centrifuged at 1500g for 5  min 
and the plasma removed. The red cells were then washed 
four times with physiological saline (0.85 %). Few drops 
of distilled water were added to lyse the cells after which 
four drops of CCl4 was added, vortexed and centrifuged 
at 1500g for 20  min to separate the hemoglobin. The 
Hemolysate was transferred into a clean glass test tube 
[21].
Each compartment of the electrophoretic tank was 
filled with Tris–EDTA Borate (TEB) buffer (pH 8.6) to a 
depth of about 2.5  cm. The cellulose acetate membrane 
was impregnated with TEB buffer and blotted with a 
tissue paper to remove excess buffer, but not allowed 
to dry. By means of an applicator, the control and test 
hemolysate samples were applied on the cellulose acetate 
membrane and carefully introduced onto the frame of the 
electrophoretic tank, with both ends in contact with the 
buffer. The lid of the tank was replaced and the tank con-
nected to a power supply of voltage 250  V and current 
50  mA, and allowed to run for 30  min. The power was 
disconnected and the membrane removed and stained 
with Ponceau S for 5 min. The excess stain was removed 
with 3 changes of 3  % acetic acid for 5  min each. The 
membrane was blotted and allowed to air-dry after which 
it was labelled and the results read against the controls 
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[22]. A combination of hemolysate from a sickle cell trait 
(AS) and HbC trait samples (ASC) served as the control.
Data analysis
Data collected was entered into Microsoft Office Excel 
2010 and analysed using Statistical Package for Social 
Sciences version 20.0 (SPSS 20.0). A summary was pre-
sented using descriptive statistics such as frequencies, 
percentages, mean and standard deviations. Chi square 
analysis was used to establish association between sick-
ling status, Hb genotypes and gender. A p value of <0.05 
was considered statistically significant.
Results
A total number of 1300 prospective and mainly replace-
ment blood donors presented to donate blood during the 
period of this study. Out of these, 1066 (82 %) were males 
and 234 (18  %) females. The study examined one hun-
dred and fifty (150) of these donors who consented to take 
part in the study. Out of these, 138 (92 %) were males and 
12 (8  %) females respectively. The mean age of the par-
ticipants was 30.5  ±  8.4  years. The youngest participant 
was 18 years and the oldest was 51 years. The age group 
of 20–24 was the highest representing 28.7 % of the total 
number of participants (Table 1). Only four (4) participants 
(first time donors) representing 2.7 % knew their sickling 
status and Hb genotype while the remaining 146 (97.3 %) 
did not know both their sickling status and Hb genotypes. 
Ninety-six (64 %) of them had not donated blood before 
but the remaining 54 (36 %) had (Table 1). Out of the 54 
that have had previous blood donation experience, 29 had 
donated blood once, 14 twice, 7 thrice and 4 four times. In 
terms of types of donors, Sixteen (16) participants repre-
senting 10.7 % were voluntary donors and the remaining 
134 representing 89.3 % were replacement donors. There 
were no commercial and autologous donors.
For the sickling status of the participants, seventeen 
(17) representing 11.3  % tested positive for sickling 
(Fig. 1a) while the remaining 133 (88.7 %) were sickling 
negative (Fig. 1b) as shown in Table 2. Twelve (8.7 %) of 
the 138 male participants tested positive for sickling with 
the remaining 126 (91.3 %) testing negative. Also, out of 
12 females, 5 (41.7  %) tested positive for sickling and 7 
(58.3 %) were sickling negative as shown in Table 2 below. 
Out of the total 150 donors, 131 (87.3 %), 2 (1.3 %) and 17 
(11.3 %) were AA, AC and AS respectively. Subsequently, 
124 (89.9 %) of the males were AA, 2 (1.4 %) were AC and 
12 (8.7 %) were AS, then 7 (58.3 %) of the females were 
AA and 5 (41.7 %) were AS with no AC (Fig. 2) (Table 2).
Discussion and conclusion
Blood transfusion is a therapeutic procedure but can be 
harmful instead of saving lives. Every blood donation and 
transfusion carries a potential risk for both the donor 
and recipient [23, 24]. Individuals with certain medical 
defects may unknowingly find themselves in the donor 
population which may have effect on their health as well 
as that of the recipient [19]. The Blood Transfusion Ser-
vices therefore, have a duty of care towards blood donors 
and recipients to make sure any contraindications are 
avoided.
Out of the total 150 blood donors involved in this 
study, 138 (92 %) were males and 12 (8 %) were females 
giving a male to female ratio of 12:1. This was high com-
pared to the gender distribution in another study that 
had a male to female ratio of 4:1 from a population of 
314 [16, 25]. The greater proportion of male donors 
compared to females in our study may be attributed 
to the fact that females are not very much encouraged 
to participate in blood donations, be it voluntary or 
replacement due to certain socio-cultural beliefs. Other 
physiological conditions may also exclude females from 
blood donation including pregnancy, lactation and 
menstruation [25]. Age distribution also showed that, 
the age group of 20–24  years had the highest number 
of blood donors (28.7  %) which is similar to the find-
ings in a study by Omisakin et al. that had age group of 
15–24 years (53.8 %) with the highest number of donors 
[16].
Table 1 Distribution of  demographic characteristics 
of participants
Variables Numbers Percentage (%)
Gender
 Male 138 92.0
 Female 12 8.0
Total 150 100
Age group
 15–19 3 2.0
 20–24 43 28.7
 25–29 37 24.7
 30–34 19 12.7
 35–39 19 12.7
 40–44 17 11.3
 ≥45 12 8
Total 150 100
Knowledge of sickling/Hb genotype status
 Yes 4 2.7
 No 146 97.3
Total 150 100
Previous donations
 Yes 54 36.0
 No 96 64.0
Total 150 100
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Only 4 (2.7  %) of the participants had knowledge of 
their sickle cell status and Hb genotype, which agrees 
with a study by Lippi et  al. that stated that most blood 
donors, especially those with SCT are not aware of their 
sickle cell status [26]. This is because individuals with 
SCT are usually asymptomatic with most of their hema-
tological parameters such as hemoglobin and red blood 
cell indices within the normal range [27]. Those with 
the knowledge of their sickling status were first time 
donors and presented themselves for donation because 
they were not aware their sickling status had any bear-
ing on them as blood donors. The prevalence of SCT—
(AS) of 11.3 % in this study was found to be lower than 
the 25–30 % quoted for Ghana and 20–40 % for Africa in 
general [7, 15]. Also, considered low in relation to studies 
done by Omisakin et al. and Zaccheaus et al. which had 
prevalence of HbS trait as 26.1 and 19.68 % respectively 
[16, 28].
It is recommended that, to achieve a safe and suf-
ficient blood supply, blood should be collected from 
voluntary non-remunerated donors who have a lower 
risk of Transfusion-transmissible infections (TTIs) 
compared to replacement and commercial donors [14]. 
However, in this study, only 10.7  % were voluntary 
donors compared to 89.3 % of replacement donors. This 
falls short of the 80–100 % voluntary donations encour-
aged in a publication by the centre for disease control of 
the WHO [29].
There is significant number of people carrying sickle 
cell trait, especially in Africa and Ghana in particular, 
who might not be aware of their carrier status before 
enrolling to be blood donors. It is therefore reasonable 
to consider the possibility of implementing a practice 
of routine screening for sickle cell trait in blood donors 
prior to donating blood or donated blood units. This way 
transfusion of HbS containing blood to recipients, which 
Fig. 1 A figure of photomicrograph results for blood obtained from a person without and with sickle cell trait. a Shows sickled red blood cells 
(black arrowed) from a person with sickle cell trait under low oxygen tension. b Represent normal red blood cells (red arrowed) from a person with 
no sickle cells trait
Table 2 Gender distribution of sickling status and hemoglobin genotype of blood donors
Gender Sickling status Hemoglobin genotype Total
Negative Positive AA AC AS
Male 126 (91.3 %) 12 (8.7 %) 124 (89.9 %) 2 (1.4 %) 12 (8.7 %) 138 (100 %)
Female 7 (58.3 %) 5 (41.7 %) 7 (58.3 %) 0 (0.0 %) 5 (41.7 %) 12 (100 %)
Total 133 (88.7 %) 17 (11.3 %) 131 (87.3 %) 2 (1.3 %) 17 (11.3 %)
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can induce further sickling in sickle cell patients, may 
be avoided. This will go a long way to help in the proper 
management of sickle cell disease patients and to estab-
lish a useful diagnosis of SCT in blood donors.
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